Questions? +1 (202) 335-3939 Login
Trusted News Since 1995
A service for medical industry professionals · Sunday, August 1, 2021 · 547,788,465 Articles · 3+ Million Readers

Generic Oncology Drugs Market Growth Sturdy at 6.3% CAGR to Outstrip $36,029.60 Million by 2027 - COVID-19 Impact and Global Analysis by TheInsightPartners.com

The Generic Oncology Drugs Market Growth impelled by increasing prevalence of cancer across the globe, growing generic drug launches and benefits offered by the generic drugs; while small molecule segment held a largest market share of 87.67% by molecule type and expected to witness the highest CAGR of 6.6% over the coming years.

/EIN News/ -- Pune, India., June 16, 2021 (GLOBE NEWSWIRE) -- Generic Oncology Drugs Market: Key Insights
According to our new research study on “Generic Oncology Drugs Market to 2027 – Global Analysis and Forecast – by Molecular Type, and Indication” the Generic Oncology Drugs Market Size was valued at US$ 21,200.00 million in 2018 and is projected to reach US$ 36,029.60 million by 2027; it is expected to grow at a CAGR of 6.3% during 2019–2027.

Generic Oncology Drugs Market: Competition Landscape and Key Developments
Teva Pharmaceutical Industries LTD., Sandoz International GMBH, Glenmark Pharmaceuticals LIMITED, Sun Pharmaceutical Industries LTD, MSN Laboratories, Aurobindo Pharma, Intas Pharmaceuticals LTD, Zydus Cadila, Mylan N.V., Shilpa Medicare LTD, Fresenius Kabi AG and Dr. Reddy’s Laboratories are among the key companies operating in the Generic Oncology Drugs market. Leading players are focusing on the new product launch, expansion and diversification of their market presence, and acquisition of new customer base, thereby tapping prevailing business opportunities.

In October 2018, Dr. Reddy's Laboratories Ltd announced the launch of Imatinib Mesylate tablets, which is a generic version of Novartis' blockbuster anti-cancer drug Gleevec, in the US market.

In July 2019, Drug maker Pfizer Inc. has agreed to spin off its generic drugs business and combine it with Mylan, a move that leaves Pfizer with more profitable innovative drugs, including cancer drug Ibrance and pneumonia vaccine Prevnar.

Get Exclusive Sample Pages of Generic Oncology Drugs Market - COVID-19 Impact and Global Analysis with Strategic Insights at https://www.theinsightpartners.com/sample/TIPRE00006393/

In 2019, North America dominated the global Generic Oncology Drugs market. The market growth in the region is attributed to rising prevalence of cancer, along with increasing awareness regarding the medical condition as well as the presence of supportive associations in the region. For instance, as per the National Cancer Institute, approximately 1,735,350 new cases of cancer were diagnosed in the country in 2018. The common cancers include breast cancer, lung & bronchus cancer, prostate cancer, colon & rectum cancer, melanoma cancer, and liver cancer. Furthermore, according to the data published by A Cancer Journal for Clinicians, in 2017, it was estimated that 1,688,780 new cases of cancer were in the US. The incidences of cancer are rising at an alarming rate in the country, which leads to increased diagnosis for the cancer treatment.

Based on molecule type, the Generic Oncology Drugs market was segmented into large molecules and small molecules. The small molecule segment held ~87.67% of the market share in 2018. On the basis of indication, the Generic Oncology Drugs market is segmented into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, kidney cancer, cervical cancer and others. The lung cancer segment held the largest market share in 2018, and it is further anticipated to register a significant CAGR during 2019–2027.

Cancer is one of the leading cause of deaths across the globe and is extremely affecting the quality of life. Thus, cancer will be burden on society if not diagnosed and treated on time. According to the World Health Organization in 2018, approximately, 9.6 million deaths across the globe were due to cancer. Furthermore the National Cancer Institute predicted that in 2018, approximately 1,735,350 new cancer cases will be diagnosed in the US.

Download Sample PDF Brochure of Generic Oncology Drugs Market Growth Research Report at https://www.theinsightpartners.com/sample/TIPRE00006393/


Figure. 1. Most Prevalent Forms of Cancers Globally, 2018

Cancer Global Number of Cases
Lung Cancer 2.09 million cases
Breast Cancer 2.09 million cases
Colorectal Cancer 1.80 million cases
Prostate Cancer 1.28 million cases
Skin cancer  1.04 million cases
Stomach Cancer 1.03 million cases

Source: The World Health Organization and The Insight Partners Analysis


Additionally, cancer is found to be common in European countries as well. As per the Cancer Research UK, in 2016, around 163,444 deaths in UK were due to cancer.

Furthermore, Asia Pacific region is also facing the problem of growing prevalence of cancer. The top 15 countries with Cancer prevalence are: Japan, Taiwan, Singapore, South Korea, Malaysia, Thailand, China, Philippines, Sri Lanka, Vietnam, Indonesia, Mongolia, India, Laos, and Cambodia. According to the National Institute of Cancer Prevention and Research (NICPR), in 2018, in India total deaths due to cancer were 784,821.

These statistics determine an increase in the demand for advanced cancer diagnostics in various regions across the globe. Thus driving the growth of generic oncology drugs during the forecast period.

Generic Oncology Drugs Market: Segmental Overview
In terms of indication, the stomach cancer segment is anticipated to register the highest CAGR in the Generic Oncology Drugs market during the forecast period. Stomach cancer occurs more in older adults and about twice as common in men in comparison with women. As per the American Cancer Society, in 2019, stomach cancer was diagnosed in approximately 27,510 cases. Among which 17,230 in men and 10,280 in women. Moreover, nearly 11,140 people are estimated to die from stomach cancer, in which 6,800 were men, and 4,340 were women. The prevalence of stomach cancer is more common in other developing countries as compared to developed countries.

Direct Purchase Copy of Generic Oncology Drugs Market Research Study at https://www.theinsightpartners.com/buy/TIPRE00006393/

Some of the common drugs prescribed for the treatment of stomach cancer includes Everolimus, Doxorubicin Hydrochloride, Trastuzumab, Mitomycin C, and others. Therefore, the rising cases of stomach cancer and the need for better therapeutic generics will grow the market in the forecast period.



Browse Related Reports:
Immuno-Oncology Drugs Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Drug Type (Immune Checkpoint Inhibitors, Monoclonal Antibodies, Cytokine Based Immunotherapy, Cancer Vaccines, CAR-T Cell Therapy,); Therapeutic Application (Melanoma, Lung Cancer, Blood Cancer, Renal Cell Carcinoma, Prostate Cancer, Bladder Cancer, Others); End User (Hospitals, Clinics, Ambulatory Surgical Centers) - https://www.theinsightpartners.com/reports/immuno-oncology-drugs-market

Oncology Drugs Market Forecast to 2028 - Covid-19 Impact and Global Analysis - By Drug Class Type ( Chemotherapy, Targeted Therapy, Immunotherapy (Biologic Therapy), Hormonal Therapy ); Indication ( Lung Cancer, Stomach Cancer, Colorectal Cancer, Breast Cancer, Prostate Cancer, Liver Cancer, Esophagus Cancer, Cervical Cancer, Kidney Cancer, Bladder Cancer, Others ) - https://www.theinsightpartners.com/reports/oncology-drugs-market



About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.

Contact Us:
If you have any queries about this report or if you would like further information, please contact us:

Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Press Release - https://www.theinsightpartners.com/pr/generic-oncology-drugs-market


Primary Logo

Powered by EIN News


EIN Presswire does not exercise editorial control over third-party content provided, uploaded, published, or distributed by users of EIN Presswire. We are a distributor, not a publisher, of 3rd party content. Such content may contain the views, opinions, statements, offers, and other material of the respective users, suppliers, participants, or authors.

Submit your press release